Engages leading marketing firm MZ Digital and crowdfunding platform Dealbuildr to successfully execute raise.
Vancouver, British Columbia–(Newsfile Corp. – June 25, 2025) – Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd“), the company behind unbuzzdTM – the scientifically-proven and game-altering beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – is pleased to announce that it has engaged MZ Digital, a global leader in online marketing, and Dealbuildr, a leading online platform for raising capital, to raise up to US$5 million through a Regulation D 506(c) offering. This format of raising capital allows businesses to sell and issue securities to accredited investors without a cap on the amount raised.
John Duffy, CEO of Unbuzzd Wellness Inc., stated, “We are dedicated to offering scientifically backed unbuzzd to alcohol consumers who want to enjoy themselves, stay in control, and feel great the next day. Our collaboration with MZ Digital and utilizing the Dealbuildr platform, will support us raise the necessary capital to support our direct-to-consumer, distributor, and retail expansion plans, allowing us to reach more consumers more often.” Mr. Duffy has over twenty years of leadership experience in the beverage indusattempt, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola.
Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, “This capital raise will give us the ability to continue to grow the company and expand sales, while positioning Unbuzzd for a future initial public offering.”
About Unbuzzd Wellness Inc.
Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blconclude of vitamins, minerals, and herbs, unbuzzd supports your body process alcohol rapider, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad tarreceive audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration (“BAC“), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:
Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent rapider within 30 minutes of consuming unbuzzd compared to control subjects. This rapider reduction of BAC after consuming unbuzzd was both statistically significant compared to placebo and was observed at each subsequent measurement of BAC over a four-hour period.
Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and built fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
Reduced Perceived Impairment and Mental Fatigue: unbuzzd supported alleviate perceived impairment and mental fatigue cautilized by alcohol intoxication.
Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
The full press release of the clinical trial can be found here.
unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at https://unbuzzd.com. unbuzzdTM is a registered trademark of Unbuzzd Wellness Inc.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
This news release contains “forward-viewing information” within the meaning of applicable Canadian securities legislation. Generally, but not always, forward-viewing information and statements can be identified by the utilize of words such as “plans”, “expects”, “intconcludes”, “estimates”, “intconcludes”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. “Forward-viewing information” includes the engagement of the investment bank; the Company completing a capital raise; the Company completing an initial public offering on a major US public exalter; the utilize of proceeds from the offering; the results of the Company’s clinical trials; the stated claims about product benefits and effectiveness; and statements about market potential and consumer demand.
Such forward-viewing information and statements are based on numerous assumptions, including the investment bank fulfilling its role as a financial advisor; the Company will complete a capital raise on the terms outlined herein; the Company will complete an initial public offering on a major US public exalter; the Company will utilize the utilize of proceeds from the offering as outlined herein; the Company will have the ability to realize upon the stated claims of product benefits and effectiveness; and the Company will have the ability to realize upon its stated claims of market potential and consumer demand.
Forward-viewing information and statements also involve known and unknown risks, and uncertainties and other factors, which may cautilize actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-viewing information or statements, the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological alter; depconcludeence on key personnel; depconcludeence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials or past clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain innotifyectual property protection for the drug product candidates of the Company; risks that the Company’s innotifyectual property and technology won’t have the intconcludeed impact on the Company and/or its business; the investment bank not fulfilling its role as a financial advisor; the Company will be unable to complete a capital raise on the terms outlined herein or at all; the Company will be unable to complete an initial public offering on a major US public exalter or at all; the Company will not utilize the utilize of proceeds from the offering as outlined herein; the Company’s inability to realize upon the stated claims of product benefits and effectiveness; and the Company’s inability to realize upon its stated claims of market potential and consumer demand.
Although the Company has attempted to identify important factors that could cautilize actual results to differ materially from those contained in the forward-viewing information or implied by forward-viewing information, there may be other factors that cautilize results not to be as anticipated, estimated or intconcludeed.
There can be no assurance that forward-viewing information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intconcludeed. Accordingly, readers should not place undue reliance on forward-viewing statements or information. The Company undertakes no obligation to update or reissue forward-viewing information as a result of new information or events except as required by applicable securities laws.
The Company builds no medical, treatment or health benefit claims about unbuzzd™. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated any claims regarding unbuzzd™. Other than as outlined herein, the efficacy of such products have not been confirmed by approved research. Further rigorous scientific research and clinical trials are requireded. Other than as outlined herein, no clinical trials for the utilize of the Company’s proposed products have been conducted. Other than outlined herein, any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials.
Leave a Reply